Objective To investigate the clinical applications of dual-source dual-energy CT and dual-energy virtual unenhanced iodine distribution technology in thoracic tumor scans.Methods CT and clinical data of 58 cases of patients with thorax tumor were analyzed.The quality score,the noise,the average lesion CT values and radiation dose were compared between dual-energy group virtual unenhanced and conventional unenhanced image.The lesion benign and malignant differential diagnosis by strengthen the distribution of iodine value in dual-energy group and strengthen the value of manual measurement in conventional CT group were compared.Results The quality scores in virtual unenhanced and conventional unenhanced image were (4.62±0.52) and (4.71±0.46) points (t =2.319,P ＞ 0.05).The noise in virtual unenhanced images and conventional unenhanced image were (8.10±1.16) and (7.30±1.06) HU (t =5.246,P＜ 0.05).The effective dose in virtual unenhanced and in conventional plain were (5.18±0.96) and (5.55±1.18) mSv (t =4.005,P ＜ 0.05).CT value distribution of iodine was correlated with enhanced CT values.Conclusions The virtual unenhanced images can show well lung disease,which meet the diagnostic requirements and may be instead of the conventional plain chest potential value.Dual-energy iodine distribution of lesions can observe blood supply more directly and more sensitively,can quantityze expression of the extent of the lesions enhanced to provide richer information for clinical diagnosis of tumor lesions.

Objective:To investigate the correlation of PELP1/MNAR expression with expressions of estrogen receptor (ER), Ki-67, human epidermal growth factor receptor 2 (HER2) and PIK3CA gene mutation.Methods:A total of 80 paraffin-embedded tissue specimens of primary invasive breast cancer patients in the Fifth People's Hospital of Datong in Shanxi Province from January 2008 to December 2018 were collected. The expression of PELP1/MNAR was examined by immunohistochemistry EliVision tow-step method. The polymerase chain reaction (PCR)-Sanger sequencing method was used to detect the mutation of PIK3CA gene. The expressions of PELP1/MNAR among patients with different expression status of ER, Ki-67, HER2 and with or without PIK3CA gene mutation were compared, and the correlations between each index and the expression of PELP1/MNAR were analyzed.Results:The high expression rates of PELP1/MNAR protein in patients with ER-positive [86.1% (31/36) vs. 59.1% (26/44)], Ki-67 high expression [100.0% (13/13) vs. 65.7% (44/67)], HER2-positive [81.0% (34/42) vs. 60.5% (23/38)] were high, and the differences were statistically significant (all P<0.05). There was no significant difference in the high expression rate of PELP1/MNAR protein between patients with mutant and wild-type PIK3CA [60.0% (12/20) vs. 75.0% (45/60), P = 0.199]. The expression of PELP1/MNAR was negatively correlated with the expression level of ER ( r = -0.195, P < 0.05), positively correlated with the expression level of Ki-67 ( r = 0.198, P < 0.05), positively correlated with the expression level of HER2 ( r = 0.225, P < 0.05), and negatively correlated with lymph node metastasis ( r = -0.269, P < 0.05). Conclusions:The expression of PELP1/MNAR in invasive breast cancer is negatively correlated with the expression level of ER, and positively correlated with the expression level of Ki-67 and HER2. There is no correlation between PELP1/MNAR expression and PIK3CA gene mutation, and the two may play their own role in the PI3K-AKT-mTOR regulatory pathway of breast cancer.